0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016–2019)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: A robust estimate of the number of people with chronic hepatitis C virus (HCV) infection is essential for an appropriate public health response and for monitoring progress toward the WHO goal of eliminating viral hepatitis. Existing HCV prevalence studies in the European Union (EU)/European Economic Area (EEA) countries are heterogeneous and often of poor quality due to non-probability based sampling methods, small sample sizes and lack of standardization, leading to poor national representativeness. This project aimed to develop and pilot standardized protocols for undertaking nationally representative HCV prevalence surveys in the general adult population.

          Methods: From 2016 to 2019 a team from the Robert Koch-Institute contracted by the European Centre for Disease Prevention and Control synthesized evidence on existing HCV prevalence surveys and survey methodology and drafted a protocol. The methodological elements of the protocol were piloted and evaluated in Bulgaria, Finland and Italy, and lessons learnt from the pilots were integrated in the final protocol. An international multidisciplinary expert group was consulted regularly.

          Results: The protocol includes three alternative study approaches: a stand-alone survey; a “nested” survey within an existing health survey; and a retrospective testing survey approach. A decision algorithm advising which approach to use was developed. The protocol was piloted and finalized covering minimum and gold standards for all steps to be implemented from sampling, data protection and ethical issues, recruitment, specimen collection and laboratory testing options, staff training, data management and analysis and budget considerations. Through piloting, the survey approaches were effectively implemented to produce HCV prevalence estimates and the pilots highlighted the strengths and limitations of each approach and key lessons learnt were used to improve the protocol.

          Conclusions: An evidence-based protocol for undertaking HCV prevalence serosurveys in the general population reflecting the different needs, resources and epidemiological situations has been developed, effectively implemented and refined through piloting. This technical guidance supports EU/EEA countries in their efforts to estimate their national hepatitis C burden as part of monitoring progress toward the elimination targets.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

          Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016

            Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. To update the estimated HCV prevalence among all adults aged ≥18 years in the United States, we analyzed 2013-2016 data from the National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of HCV in the noninstitutionalized civilian population and used a combination of literature reviews and population size estimation approaches to estimate the HCV prevalence and population sizes for four additional populations: incarcerated people, unsheltered homeless people, active-duty military personnel, and nursing home residents. We estimated that during 2013-2016 1.7% (95% confidence interval [CI], 1.4-2.0%) of all adults in the United States, approximately 4.1 (3.4-4.9) million persons, were HCV antibody-positive (indicating past or current infection) and that 1.0% (95% CI, 0.8-1.1%) of all adults, approximately 2.4 (2.0-2.8) million persons, were HCV RNA-positive (indicating current infection). This includes 3.7 million noninstitutionalized civilian adults in the United States with HCV antibodies and 2.1 million with HCV RNA and an estimated 0.38 million HCV antibody-positive persons and 0.25 million HCV RNA-positive persons not part of the 2013-2016 NHANES sampling frame. Conclusion: Over 2 million people in the United States had current HCV infection during 2013-2016; compared to past estimates based on similar methodology, HCV antibody prevalence may have increased, while RNA prevalence may have decreased, likely reflecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality among the HCV-infected population; efforts on multiple fronts are needed to combat the evolving HCV epidemic, including increasing capacity for and access to HCV testing, linkage to care, and cure.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study

              The World Health Organization aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030. Injecting drug use (IDU) is an important risk factor for HCV transmission, but the contribution to country-level and global epidemics is unknown. We estimated the contribution of IDU-associated risk to HCV epidemics at country and global levels. A dynamic, deterministic HCV transmission model simulated country-level HCV epidemics among people who inject drugs (PWID) and the general population. Each country’s model was calibrated using country-specific data from UN datasets and systematic reviews on the prevalence of HCV and IDU. The population attributable fraction (tPAF) of HCV transmission associated with IDU was estimated, defined here as the percentage of HCV infections prevented if additional HCV transmission due to IDU was removed between 2018–2030. The model included 88 countries (85% of the global population). The model predicted 0.2% of individuals were PWID in 2017 and 8% of prevalent HCV infections were among people who recently injected drugs. Globally, if elevated HCV transmission risk among PWID was removed, an estimated 43% (95% credibility interval [CrI]: 25%−67%), the tPAF, of incident HCV infections would be prevented from 2018–2030, varying regionally. The tPAF was higher (79%, CrI: 57%−97%) in high-income countries than low and middle-income countries (38%, CrI: 24%−64%) and was associated with the percentage of a country’s prevalent infections that are among PWID. Unsafe injecting practices among PWID contribute substantially to incident infections globally; any intervention that can reduce transmission among PWID will have a pronounced effect on country level incidence. NIHR
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Public Health
                Front Public Health
                Front. Public Health
                Frontiers in Public Health
                Frontiers Media S.A.
                2296-2565
                28 May 2021
                2021
                : 9
                : 568524
                Affiliations
                [1] 1Department of Infectious Disease Epidemiology, Robert Koch Institute , Berlin, Germany
                [2] 2Charité, Universitätsmedizin Berlin , Berlin, Germany
                [3] 3Independent consultant , Madrid, Spain
                [4] 4Department of Health Security, Finnish Institute for Health and Welfare , Helsinki, Finland
                [5] 5Department of Infectious Disease, Istituto Superiore di Sanità , Rome, Italy
                [6] 6Regional Health Inspectorate , Stara Zagora, Bulgaria
                [7] 7European Centre for Disease Prevention and Control , Stockholm, Sweden
                Author notes

                Edited by: John Ward, Task Force for Global Health, United States

                Reviewed by: John Shearer Lambert, University College Dublin, Ireland; Kathryn Jack, Nottingham University Hospitals NHS Trust, United Kingdom; Nicola Singleton, Independent Researcher, Ridgmont, Bedfordshire, United Kingdom; Liesl Hagan, Centers for Disease Control and Prevention (CDC), United States

                *Correspondence: Ida Sperle sperle-heupeli@ 123456rki.de

                This article was submitted to Public Health Policy, a section of the journal Frontiers in Public Health

                †These authors share last authorship

                Article
                10.3389/fpubh.2021.568524
                8193123
                24c84451-f6d5-4dc0-a4c2-d89ff5ec8985
                Copyright © 2021 Sperle, Nielsen, Bremer, Gassowski, Brummer-Korvenkontio, Bruni, Ciccaglione, Kaneva, Liitsola, Naneva, Perchemlieva, Spada, Toikkanen, Amato-Gauci, Duffell and Zimmermann.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 09 September 2020
                : 28 April 2021
                Page count
                Figures: 2, Tables: 1, Equations: 0, References: 37, Pages: 12, Words: 8388
                Funding
                Funded by: European Centre for Disease Prevention and Control 10.13039/501100000805
                Categories
                Public Health
                Original Research

                hepatitis c,hcv,general population,prevalence,technical protocol,surveys,questionnaires

                Comments

                Comment on this article